Voluntary announcement - SYS6088 injection (a tri-specific antibody) obtains clinical trial approval in China
Filed with HKEX · Stock code 1093 · · 2 pages · English
Summary by 6ix AI
The product targets programmed cell death protein one, vascular endothelial growth factor A, and cytotoxic T-lymphocyte-associated antigen four, aiming to enhance anti-tumor effects. The approved trials will focus on advanced or metastatic solid tumors, with preclinical studies indicating significant anti-tumor activity and a favorable safety profile.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
CSPC Pharmaceutical Group Limited on 6ix
Earlier from CSPC Pharmaceutical
- Voluntary announcement - SYS6062 (antibody-drug conjugate) obtains clinical trial approval in China
- Voluntary announcement - data from Phase I clinical study of SYS6002 as monotherapy for the treatment of advanced cervical cancer presented as a rapid oral presentation at the 2026 annual global meeting of the international gynecologic cancer society (igcs 2026)
- Voluntary announcement - latest updates from 8 clinical trials to be presented at the ESMO congress 2026
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Voluntary announcement - results of phase III clinical study of efmedaglutide alfa injection in combination with metformin in chinese adult patients with type 2 diabetes mellitus presented in a short oral discussion at the 62nd annual meeting of the european association for the study of diabetes (easd 2026)
Later from CSPC Pharmaceutical
- Voluntary announcement - grant of awarded shares pursuant to the 2018 share award scheme
- Voluntary announcement - grant of awarded shares pursuant to the 2026 share award scheme
- Voluntary announcement - phase i clinical trial of SYH2083 eye drops for the treatment of dry eye disease officially initiated in china
- Voluntary announcement - phase ii clinical trial of SYH2066 for the treatment of respiratory syncytial virus infection officially initiated in china
- Voluntary announcement - phase iii clinical trial of SYS6043 for the first-line treatment of unresectable recurrent or metastatic triple-negative breast cancer officially initiated in china
Follow CSPC Pharmaceutical into a list and get an email when it puts out news.
Follow CSPC Pharmaceutical